Development and course of heart failure after a myocardial infarction in younger and older people

Background Acute myocardial infarction (AMI) is a common cause of heart failure (HF), which can develop soon after AMI and may persist or resolve or develop late. HF after an MI is a major source of mortality. The cumulative incidence, prevalence and resolution of HF after MI in different age groups are poorly described. This study describes the natural history of HF after AMI according to age. Methods Patients with AMI during 1998 were identified from hospital records. HF was defined as treatment of symptoms and signs of HF with loop diuretics and was considered to have resolved if loop diuretic therapy could be stopped without recurrence of symptoms. Patients were categorised into those aged < 65 years, 65–75 years, and > 75 years. Results Of 896 patients, 311, 297 and 288 were aged < 65, 65–75 and >75 years and of whom 24%, 57% and 82% had died respectively by December 2005. Of these deaths, 24 (8%), 68 (23%) and 107 (37%) occurred during the index admission, many associated with acute HF. A further 37 (12%), 63 (21%) and 82 (29%) developed HF that persisted until discharge, of whom 15, 44 and 62 subsequently died. After discharge, 53 (24%), 55 (40%) and 37 (47%) patients developed HF for the first time, of whom 26%, 62% and 76% subsequently died. Death was preceded by the development of HF in 35 (70%), 93 (91%) and 107 (85%) in aged < 65 years, 65–75 years and >75 years, respectively. Conclusions The risk of developing HF and of dying after an MI increases progressively with age. Regardless of age, most deaths after a MI are preceded by the development of HF.

[1]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[2]  F. Harrell,et al.  Regression modelling strategies for improved prognostic prediction. , 1984, Statistics in medicine.

[3]  Eric Boersma,et al.  Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour , 1996, The Lancet.

[4]  J. Tijssen,et al.  Short- and long-term recovery of left ventricular function predicted at the time of primary percutaneous coronary intervention in anterior myocardial infarction. , 2004, Journal of the American College of Cardiology.

[5]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[6]  J. Boura,et al.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .

[7]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[8]  J. Daubert,et al.  Cardiac resynchronization therapy: are modern myths preventing appropriate use? , 2009, Journal of the American College of Cardiology.

[9]  GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. , 1994, Lancet.

[10]  J. Cleland,et al.  Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: A report from the SPORTIF III and V trials , 2007, European journal of heart failure.

[11]  W. Rogers,et al.  The volume of primary angioplasty procedures and survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. , 2000, The New England journal of medicine.

[12]  L. Wilhelmsen,et al.  Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. , 2001, European heart journal.

[13]  G. Parodi,et al.  Prevalence, predictors, time course, and long-term clinical implications of left ventricular functional recovery after mechanical reperfusion for acute myocardial infarction. , 2007, The American journal of cardiology.

[14]  A. D. Cunningham,et al.  Post-traumatic focal true left ventricular aneurysm , 2004, Heart.

[15]  F H Sheehan,et al.  The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. , 1987, Circulation.

[16]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .

[17]  R. Burrow,et al.  Heart , 2013, Feline Soft Tissue and General Surgery.

[18]  A. Parkhomenko,et al.  Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction ≤30% , 2006, European journal of heart failure.

[19]  M. Pfeffer,et al.  VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context , 2003, European journal of heart failure.

[20]  M L Simoons,et al.  A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). , 2002, European heart journal.

[21]  Jeroen J. Bax,et al.  Impact of time to reperfusion after acute myocardial infarction on myocardial damage assessed by left ventricular longitudinal strain. , 2009, The American journal of cardiology.

[22]  M. Gotsman,et al.  Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. , 1985, The New England journal of medicine.

[23]  Robert M Califf,et al.  Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.

[24]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[25]  P. Quandalle,et al.  The effect of ageing on cardiac remodelling and hospitalization for heart failure after an inaugural anterior myocardial infarction. , 2008, European heart journal.

[26]  A. Rigby,et al.  The timing of development and subsequent clinical course of heart failure after a myocardial infarction. , 2008, European heart journal.

[27]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[28]  M. Morice,et al.  Is the volume-outcome relation still an issue in the era of PCI with systematic stenting? Results of the greater Paris area PCI registry. , 2006, European heart journal.

[29]  G. Montalescot,et al.  High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. , 2012, European heart journal.

[30]  J. Herlitz,et al.  Survival, mode of death, reinfarction and use of medication during a period of 5 years after acute myocardial infarction in different age groups. , 1996, Cardiology.

[31]  Samuel O. M. Manda,et al.  Evaluation of risk scores for risk stratification of acute coronary syndromes in the Myocardial Infarction National Audit Project (MINAP) database , 2008, Heart.

[32]  Marc P. Bonaca,et al.  Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.

[33]  L. Morrison,et al.  Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. , 2000, JAMA.

[34]  P. Herbison,et al.  Clinical outcome of older patients with acute coronary syndrome over the last three decades. , 2006, Age and ageing.

[35]  Á. Avezum,et al.  Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). , 2005, American heart journal.

[36]  L. Køber,et al.  Influence of age on the prognostic importance of left ventricular dysfunction and congestive heart failure on long-term survival after acute myocardial infarction. TRACE Study Group. , 1996, American Journal of Cardiology.